Histamine-2 Receptor Antagonists vs Proton Pump Inhibitors on Gastrointestinal Tract Hemorrhage and Infectious Complications in the Intensive Care Unit

被引:152
|
作者
MacLaren, Robert [1 ]
Reynolds, Paul M. [2 ]
Allen, Richard R. [3 ]
机构
[1] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Dept Clin Pharm, Aurora, CO 80045 USA
[2] Univ Colorado Hosp, Dept Pharm, Aurora, CO USA
[3] Peak Stat Serv, Evergreen, CO USA
关键词
STRESS-ULCER PROPHYLAXIS; VENTILATOR-ASSOCIATED PNEUMONIA; COMMUNITY-ACQUIRED PNEUMONIA; SUPPRESSIVE MEDICATION USE; CRITICALLY III PATIENTS; BLEEDING PROPHYLAXIS; RISK-FACTORS; RANITIDINE; SUCRALFATE; PREVENTION;
D O I
10.1001/jamainternmed.2013.14673
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE Histamine-2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) are commonly used to prevent gastrointestinal tract (GI) hemorrhage in critically ill patients. The stronger acid suppression of PPIs may reduce the rate of bleeding but enhance infectious complications, specifically pneumonia and Clostridium difficile infection (CDI). OBJECTIVE To evaluate the occurrence and risk factors for GI hemorrhage, pneumonia, and CDI in critically ill patients. DESIGN, SETTING, AND PARTICIPANTS A pharmacoepidemiological cohort study was conducted of adult patients requiring mechanical ventilation for 24 hours or more and administered either an H(2)RA or PPI for 48 hours or more while intubated across 71 hospitals between January 1, 2003, and December 31, 2008. Propensity score-adjusted and propensity-matched multivariate regression models were used to control for confounders. MAIN OUTCOMES AND MEASURES Primary outcomes were secondary diagnoses of International Classification of Diseases, Ninth Revision (ICD-9)-coded GI hemorrhage, pneumonia, and CDI occurring 48 hours or more after initiating invasive ventilation. RESULTS Of 35 312 patients, 13 439 (38.1%) received H2RAs and 21 873 (61.9%) received PPIs. Gastrointestinal hemorrhage (2.1% vs 5.9%; P <.001), pneumonia (27% vs 38.6%; P <.001), and CDI (2.2% vs 3.8%; P <.001) occurred less frequently in the H2RA group. After adjusting for propensity score and covariates, odds ratios of GI hemorrhage (2.24; 95% CI, 1.81-2.76), pneumonia (1.2; 95% CI, 1.03-1.41), and CDI (1.29; 95% CI, 1.04-1.64) were greater with PPIs. Similar results were obtained in the propensity-matched models of 8799 patients in each cohort. CONCLUSIONS AND RELEVANCE Proton pump inhibitors are associated with greater risks of GI hemorrhage, pneumonia, and CDI than H2RAs in mechanically ventilated patients. Numerous other risk factors are apparent. These data warrant confirmation in comparative prospective studies.
引用
收藏
页码:564 / 574
页数:11
相关论文
共 50 条
  • [41] Do Histamine-2 Receptor Antagonists and Proton Pump Inhibitors Really Have No Effect on the Gastric Emptying Rate?: Author's Reply
    Nonaka, Takashi
    Inamori, Masahiko
    JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, 2011, 17 (04) : 435 - 435
  • [42] Delirium risk of histamine-2 receptor antagonists and proton pump inhibitors: A study based on the adverse drug event reporting database in Japan
    Kikkawa, Nao
    Sogawa, Rintaro
    Monji, Akira
    Sumi, Shintaro
    Murakawa-Hirachi, Toru
    Kubo, Toshiki
    Eguchi, Yuko
    Miyamoto, Yuki
    Kamo, Masahiro
    Tobita, Shuko
    Yukawa, Misako
    Uchida, Rina
    Egoshi, Masayoshi
    Shimanoe, Chisato
    GENERAL HOSPITAL PSYCHIATRY, 2021, 72 : 88 - 91
  • [43] Comparing the Safety and Efficacy of Proton Pump Inhibitors and Histamine-2 Receptor Antagonists in the Management of Patients With Peptic Ulcer Disease: A Systematic Review
    Begg, Maha
    Tarhuni, Mawada
    Fotso, Monique N.
    Gonzalez, Natalie A.
    Sanivarapu, Raghavendra R.
    Osman, Usama
    Kumar, Abishek Latha
    Sadagopan, Aishwarya
    Mahmoud, Anas
    Khan, Safeera
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (08)
  • [44] Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoea
    Weiss, Karl
    Louie, Thomas
    Miller, Mark A.
    Mullane, Kathleen
    Crook, Derrick W.
    Gorbach, Sherwood L.
    BMJ OPEN GASTROENTEROLOGY, 2015, 2 (01):
  • [45] Proton Pump Inhibitors Versus Histamine 2 Receptor Antagonists for Stress Ulcer Prophylaxis
    Sadaka, Farid
    Trottier, Steven
    Smith, Timothy
    VanSlette, Jeffrey
    Kasal, Jan
    Palagiri, Ashok
    Subramanian, Sanjay
    CRITICAL CARE MEDICINE, 2013, 41 (12)
  • [46] Prolonged Use of Proton Pump Inhibitors, but Not Histamine-2 Receptor Antagonists, Is Associated With Lower Bone Mineral Density in Males Aged Over 70
    Gao, Shihua
    Song, Wenting
    Lin, Tianye
    Chen, Wenhuan
    He, Wei
    Wei, Qiushi
    Li, Ziqi
    FRONTIERS IN MEDICINE, 2021, 8
  • [47] Healthcare costs of GERD and acid-related conditions in pediatric patients, with comparison between histamine-2 receptor antagonists and proton pump inhibitors
    Kothari, S.
    Nelson, S. P.
    Wu, E. Q.
    Beaulieu, N.
    McHale, J. M.
    Dabbous, O. H.
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (11) : 2703 - 2709
  • [48] Impact of short-term proton pump inhibitors vs. histamine-2 receptor antagonists on gut microbiota in patients with acute coronary syndrome: A multicenter randomized trial
    Chen Chen
    Liang Huizhu
    He Meibo
    Duan Ruqiao
    Guan Yu
    Wang Fangfang
    Duan Liping
    中华医学杂志英文版, 2025, 138 (05)
  • [49] Infectious complications associated with histamine2-receptor antagonists
    不详
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 1998, 19 (04): : 285 - 285
  • [50] Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy
    Rackoff, A
    Agrawal, A
    Hila, A
    Mainie, I
    Tutuian, R
    Castell, DO
    DISEASES OF THE ESOPHAGUS, 2005, 18 (06): : 370 - 373